Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC

Nat Rev Clin Oncol. 2015 Sep;12(9):508-9. doi: 10.1038/nrclinonc.2015.137. Epub 2015 Aug 11.

Authors

Joseph Gligorov¹, Sandrine Richard¹

Affiliation

¹ Breast Cancer Expert Centre, Medical Oncology Service, Assistance Publique-Hôpitaux de Paris (AP-HP) Tenon, Institut Universitaire de Cancérologie-Université Pierre-et-Marie-Curie (IUC-UPMC), Sorbonne University, 4 Rue de la Chine, Paris 75020, France.

PMID: 26260040
DOI: 10.1038/nrclinonc.2015.137

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / administration & dosage*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Drug Administration Schedule
Drug Synergism
Female
Humans
Neoplasm Metastasis
Paclitaxel / administration & dosage*
Randomized Controlled Trials as Topic

Substances

Bevacizumab
Paclitaxel